Postoperative adjuvant therapy for patients with resected non-small cell lung cancer: Still controversial after all these years

Chest

Volumn 117, Issue 4 SUPPL. 1, 2000, Pages 110S-118S

  Wagner Jr , Henry ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

BINDING SITE; BRAIN RADIATION; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL TRIAL; CONFERENCE PAPER; EARLY DIAGNOSIS; HIGH RISK POPULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; META ANALYSIS; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL;

EID: 0343673916     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.117.4_suppl_1.110S     Document Type: Conference Paper

References (56)

1. Williams DE, Pairolero PC, Davis CS, et al. Survival of patients surgically treated for stage I lung cancer. J Thorac Cardiovasc Surg 1981; 82:70-76
2. Wagner H, Bonomi P. Preoperative and postoperative therapy for non-small cell lung cancer. In: Roth J, Ruckdeschel J, Weisenburger T, eds. Thoracic oncology. Philadelphia, PA: W.B. Saunders, 1995; 147-163
3. Feld R, Rubenstein L, Weisenberger T, et al. Sites of recurrence in resected stage I non-small-ell lung cancer: a guide for future studies. J Clin Oncol 1984; 2:1352-1358
4. Pairolero P, Williams D, Bergstralh M, et al. Post-surgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann Thorac Surg 1984; 38:331-338
5. Thomas P, Rubinstein L, for the Lung Cancer Study Group. Cancer recurrence after resection: T1N0 non-small cell lung cancer. Ann Thorac Surg 1990; 49:242-247
6. Martini N, Flehinger B, Nagasaki F, et al. Prognostic significance of N1 disease in carcinoma of the lung. J Thorac Cardiovasc Surg 1983; 86:646-653
7. Martini N, Flehinger B. The role of surgery in N2 lung cancer. Surg Clin North Am 1987; 67:1037-1049
8. Sawyer T, Bonner J, Gould P, et al. The impact of surgical adjuvant thoracic radiation therapy for patients with non-small cell lung carcinoma with ipsilateral mediastinal lymph node involvement. Cancer 1997; 80:1399-1408
9. 2 Non-small cell lung cancer (NSCLC): heterogeneity of prognosis and evidences for a subclassification. Proc ASCO 1999; 18:1802
10. Van Houtte P, Mornex F, Rocmans P. Limites et perspectives de la radiotherapie postoperatoire dans le cancer bronchique. Cancer Radiother 1998; 2:252-259
11. Emami B, Kaiser L, Simpson J, et al. Postoperative radiation therapy in non-small cell lung cancer. Am J Clin Oncol 1997; 20:441-448
12. Larssen S. Pretreatment classification and staging of bronchogenic carcinoma. Scand J Thorac Cardiovasc Surg 1973; 10:1-47
13. Choi N, Grillo H, Gardiello M, et al. Basis of new strategies in postoperative radiotherapy of bronchogenic carcinoma. Int J Radiat Oncol Biol Phys 1980; 6:31-35
14. Green N, Kurohara S, George F, et al. Postresection irradiation for primary lung cancer. Radiology 1975; 116: 405-407
15. The Lung Cancer Study Group. Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. N Engl J Med 1986; 315:1377-1381
16. Stephens R, Girling D, Bleehen N, et al. The role of post-operative radiotherapy in non-small-cell lung cancer: a multicentre randomised trial in patients with pathologically staged T1-2, N1-2, MO disease. Br J Cancer 1996; 73:632-639
17. Dautzenberg B, Arriagada R, Chammard A, et al. A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma. Cancer 1999; 86:265-273
18. Bonner J. The role of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma: seeking to optimize local control and survival while minimizing toxicity. Cancer 1999; 86:195-196
19. Patterson G, lives R, Ginsberg R, et al. The value of adjuvant radiotherapy in pulmonary and chest wall resection for bronchogenic carcinoma. Ann Thorac Surg 1982; 34: 692-697
20. Bangma P. Post-operative radiotherapy. In: Deely T, ed. Modern radiotherapy: carcinoma of the bronchus. New York, NY: Appleton-Century-Crofts, 1971; 163-170
21. Van Houtte P, Rocmans P, Smets P, et al. Postoperative radiation therapy in lung cancer: a controlled trial after resection of curative design. Int J Radiat Oncol Biol 1980; 6:983-986
22. Israel L, Bonadonna G, Sylvester R, et al. Controlled study with adjuvant radiotherapy, chemotherapy, immunotherapy, and chemoimmunotherapy in operable squamous carcinoma of the lung. In: Muggia F, Rozencweig , eds. Lung cancer: progress in therapeutic research. New York, NY: Raven Press, 1979
23. Debevec M, Bitenc M, Vidmar S, et al. Postoperative radiotherapy for radically resected N2 non-small-cell lung cancer (NSCLC): randomised clinical study, 1988-1992. Lung Cancer 1996:14:99-107
24. Mei W, Xianzhi G, Weibo Y, et al. Randomized clinical trial of post-operative irradiation after surgery for non-small cell lung carcinoma. Lung Cancer 1994; 10:388
25. Ricci S, Milani F, Gramaglia A, et al. Surgery vs. surgery + radiotherapy in T2N1-2 non-small cell lung carcinoma: an analysis of mean term data [abstract]. Lung Cancer 1991; 7:99
26. Lafitte JJ, Ribet ME, Prevost BM, et al. Postresection irradiation for T2N0M0 non-small cell carcinoma: a prospective, randomized study. Ann Thorac Surg 1996; 62:830-834
27. Phlips P, Rocmans P, Vanderhoef P, et al. Postoperative radiotherapy after pneumonectomy: Impact of modern treatment facilities. Int J Radiat Oncol Biol Phys 1993; 27:525-529
28. Schraube P, von Kampen M, Oetzel D, et al. The impact of 3-D radiotherapy planning after a pneumonectomy compared to a conventional treatment set-up. Radiother Oncol 1995; 37:65-70
29. PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 1998; 352:257-263
30. Bonomi P, Faber L. Postoperative and preoperative chemotherapy for non-small cell lung cancer. Cancer Control 1997; 4:297-306
31. Giaccone G, Manegold C, Rossel R, et al. An update on European randomized studies in non-small cell lung cancer. Semin Oncol 1998; 4:11-17
32. Le Chevalier T. Adjuvant chemotherapy in non-small cell lung cancer. Semin Oncol 1998; 25:62-65
33. Niiranen A, Niitamo-Korhonen S, Kouri M, et al. Adjuvant chemotherapy after radical surgery for non-small cell lung cancer: a randomized study. J Clin Oncol 1992; 10:1927-1932
34. Feld R, Rubenstin L, Thomas P, et al. Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small cell lung cancer. J Natl Cancer Inst 1993; 85:299-306
35. The Study Group of Adjuvant Chemotherapy for Lung Cancer. A randomized trial of adjuvant postoperative chemotherapy in non-small cell lung cancer (the second cooperative study). Eur J Surg Oncol 1995; 21:69-77
36. Wada H, Hitomi S, Teramatsu T, et al. Adjuvant chemotherapy after complete resection in non-small cell lung cancer. J Clin Oncol 1996; 14:1048-1054
37. Holmes E, Gail M. Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma. J Clin Oncol 1986; 4:710-715
38. Figlin R, Piantadosi S. A phase 3 randomized trial of immediate combination chemotherapy vs. delayed combination chemotherapy in patients with completely resected Stage II and III non-small cell carcinoma of the lung. Chest 1994; 106:310-312
39. Dautzenberg B, Chastang C, Arriagada R, et al. Adjuvant radiotherapy versus combined sequential chemotherapy followed by radiotherapy in the treatment of resected non-small cell lung carcinoma. Cancer 1995; 76:779-786
40. Ohta M, Tsuchiya R, Shimoyama M, et al. Adjuvant chemotherapy for completely resected stage III non-small-cell lung cancer: results of a randomized prospective study. J Thorac Cardiovasc Surg 1993; 106:703-708
41. Lad T. The comparison of CAP chemotherapy and radiotherapy to radiotherapy alone for resected lung cancer with positive margin or involved highest sampled paratracheal node (Stage IIIA). Chest 1994; 106(suppl):302S-306S
42. Keller S, Adak S, Wagner H, et al. Prospective randomized trial of postoperative adjuvant therapy in patients with completely resected Stages II and IIIA non-small cell lung cancer: an Intergroup trial (E3590) [abstract 1793]. Proc Am Soc Clin Oncol 1999; 18:465A
43. Takada F, Yanagihara K, Ohtake Y, et al. p53 status predicts the efficacy of postoperative oral administration of tegafur for completely resected non-small cell lung cancer. Jpn J Clin Oncol 1999; 90:432-438
44. Schiller J, Adak S, Feins R, et al. Prognostic significance of p53 and K-RAS mutations in primary resected non-small cell lung cancer: preliminary results from a prospective randomized trial of postoperative adjuvant therapy (Intergroup Trial 0115) [abstract 1789]. Proc Am Soc Clin Oncol 1999; 18:464A
45. Auperin A, Arriagada R, Pignon J-P, et al. Prophylactic cranial irradiation for patients with small cell lung cancer in complete remission. N Engl J Med 1999; 341:476-484
46. Figlin R, Piantadosi S, Feld R, et al. Intracranial recurrence of carcinoma after complete surgical resection of stage I, II and III non-small cell lung cancer. N Engl J Med 1988; 318:1300-1305
47. Law A, Daly B, Madsen M, et al. High incidence of isolated brain metastases (CNSMets) following complete response (CR) in advanced non-small cell lung cancer (NSCLC): a new challenge [abstract 248]. Lung Cancer 1997; 18:65
48. Eberhardt W, Wilke H, Stusschke M, et al. Preoperative chemotherapy and chemoradiotherapy based on hyperfractionated accelerated radiotherapy followed by surgery in locally advanced (LAD) inoperable NSCLC stages IIIA and IIIB: the value of PCI [abstract 249]. Lung Cancer 1997; 18:65
49. Stuschke M, Eberhardt W, Pottgen C, et al. Prophylactic cranial irradiation in locally advanced non-small cell lung cancer after multimodality treatment: long-term follow-up and investigation of late neuropsychologic effects. J Clin Oncol 1999; 17:2700-2709
50. Cox J, Petrovich Z, Paig C, et al. Prophylactic cranial irradiation in patients with inoperable carcinoma of the lung. Cancer 1978; 42:1135-1140
51. Russell A, Pajak T, Selim H, et al. Prophylactic cranial irradiation for lung cancer patients at high risk for development of cerebral metastases: results of a prospective randomized trial conducted by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1991; 21:637-643
52. Umsawadi T, Valdivieso M, Chen T, et al. Role of elective brain irradiation during combined chemoradiotherapy for limited disease non-small cell lung cancer. J Neurooncol 1984; 2:253-259
53. Komaki R. Neuropsychological functioning of patients with small cell lung cancer prior to and shortly following prophylactic cranial irradiation: evidence for pre-existing cognitive impairments [abstract 1084]. Proc Am Soc Clin Oncol 1993; 12:327
54. van Oosterhout AG, van de Pol M, ten Velde GP, et al. Neurologic disorders in 203 consecutive patients with small cell lung cancer: results of a longitudinal study. Cancer 1996; 77:1434-1441
55. Martini N, Bains M, Burt M, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995; 109:120-129
56. Tockman M, Erozan Y, Gupta P, et al. The early detection of second primary lung cancers by sputum immunostaining. Chest 1994; 106(suppl):385S-390S